Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.

smoldering myeloma

Home/Tag:smoldering myeloma
7 12, 2012

To treat or not to treat smoldering myeloma

Tags: , , , , |0 Comments

There will be a lot of new information on MGUS and smoldering myeloma here at ASH this year. Dr. Jesus San-Miguel is kicking-things-off here right now, discussing the pros and cons of treating smoldering myeloma patients. In general, European studies show no advantage to treating smoldering patients early.  However, treating patients at highest risk of

5 05, 2011

While We Are Waiting For Meaningful, Patient Related News From Myeloma Workshop In Paris: Fascinating Article About Using Vaccines To Stop Multiple Myeloma Before It Starts…

Tags: , , |1 Comment

Check this out... Easy to read, yet detailed article from MIT's Technology Review about using vaccines to fight multiple myeloma.  Click-on the headline below to access the article: Biomedicine A Vaccine to Attack Cancer Early A startup is developing the first vaccine to target patients before they develop cancer. Wednesday, May 4, 2011 - By

17 04, 2011

New Smoldering Myeloma Vaccine On The Horizon

Tags: , , , |4 Comments

I don't write enough about smoldering myeloma.  This "pre-bone marrow cancer" certainly isn't addressed regularly by established pharmaceutical companies. So I thought I would share this news release I found on the Boston Business Journal earlier this weekend, about a new drug company which is betting it's future on an experimental, anti-smoldering myeloma vaccine: OncoPep

5 12, 2010

Celgene Revlimid Study Shows Success Slowing Down The Onset Of Symptomatic Multiple Myeloma In Smoldering Multiple Myeloma Patients

Tags: , , |2 Comments

Potentially good news for smoldering multiple myeloma patients from yesterday's poster sessions here at ASH:PHASE III STUDY EVALUATING REVLIMID® IN PATIENTS WITH HIGH-RISK SMOLDERING MULTIPLE MYELOMA REPORTED STATISTICALLY SIGNIFICANT REDUCTION IN RISK OF DISEASE PROGRESSION Study Showed Overall Response Rate of 91% for Patients Who Completed Initial 9 Treatment Cycles BOUDRY, SWITZERLAND - (December 4,

4 12, 2010

Live Coverage From IMF’s Multiple Myeloma Expert Panel Discussion Friday, December 3rd from the annual American Society of Hematology Meetings

Tags: , , , , , , , , |0 Comments

Good evening from the Grand Ballroom at the Peabody Hotel in Orlando, Florida.  I'm covering the IMF’s ASH kick-off event, Key Myeloma Questions for 2010: Latest Developments int Diagnosis, Prognosis and Risk Assessment in Multiple Myeloma.This should be of special interest to a cyber friend of mine, Thomas from Germany. Thomas contacted me three or four

31 08, 2009

How Does A Physician Know Your Myeloma Is Active?

Tags: , , , |0 Comments

Friday afternoon at the IMF conference in Edina, Minnesota we learned, in detail, the criteria for diagnosis in multiple myeloma. Mayo Clinic transplant nurse Teresa Micelli explained there are four basic disorders that affect plasma cells in the bone marrow. Monoclonal gammopathy of undetermined significance (MGUS), smoldering (indolent) myeloma, plasmacytoma and active myeloma. MGUS and

26 07, 2009

Jerry Walton

Tags: |3 Comments

I sat next to a thoughtful, pleasant gentleman during our meetings in Boston last week named Jerry. I received this kind e-mail from him about my book, Living with Multiple Myeloma yesterday:Pat, thanks to a delay getting out of Boston airport Tuesday night, and the hour and a half flight to Norfolk, VA, I was